Table 4.
Retrospective studies of sorafenib in older adults with advanced HCC.
| Author (n=older adults) |
Median Age (years) (range) |
Baseline Characteristics | Overall Survival |
Time to Progression |
Toxicity / Dosing | |
|---|---|---|---|---|---|---|
| Patient | Disease | |||||
| Wong 201182 (n=35) | 73 (70–85) | ECOG 0: 25.7% ECOG 1: 60% DM: 31.4% CVD: 45.7% |
CPA 62.9% CPB: 37.1% BCLC C: 91.4% Cirrhosisetiology: HCV 11.4% HBV 65.7% |
5.32 mo | 2.99 mo | Grade 3–4: 68.6% Dose interruption: 42.9% |
| Di Costanzo 201380 (n=60) | 73 (70–85) | ECOG 0: 81.7% ECOG 1: 18.3% DM: 31.7% CVD: 46.7% Average Albumin: 3.7 |
CPA 90% CPB: 10% BCLC C: 76.7% CLIP <3: 60% Cirrhosisetiology: HCV 78.3% HBV 8.3% Non-viral 8.3% |
16 mo | 12 mo | Grade 3–4: 15.7% |
| Montella 201377 (n=60) | 76 (70–90) | ECOG: n/a DM: 28% CVD: 45% |
CPA 73% CPB: 22% BCLC C: 22% Cirrhosisetiology: HCV 68% HBV 5% EtOH 1% |
10 mo | 7 mo | No Grade 2–4 registered Reduced dose: 81.7% At 2 months: lADLs: 15% improved 15% reduced; ADLs: 9% improved 4% reduced |
| Edeline 201578 (n=51 ) | Median age (range)–n/a 70–74: 53% 75–79: 35% 80+: 12% |
ECOG 1: 49% HTN: 54.9% CCI: 51%, 29.4%, 19.6% |
CPB: 7.7% Cirrhosisetiology: HCV 5.9% HBV 5.9% EtOH 54.9% NASH 35.3% |
12.6 mo | 5.6 mo | Grade 3+: 51% Reduced dose: 58.8% Hospitalization: 13.7% |
| Willet 201781 (n=51 ) | 78 (75–92) | ECOG 0: 49% ECOG 1: 49% HTN: 68.6% Average Albumin: 3.6 Median CCI: 14 |
CPA 84.3% CPB: 3.9% BCLC C: 74.5% Cirrhosisetiology: HCV 5.9% HBV 5.9% EtOH 54.9% NASH 35.3% |
15 mo | n/a | Grade 3–4: 66.7% Reduced dose: 41.2% Discontinuation due to toxicity: 60.8% |
| Arora 201879 (n=31 ) | 70 (65–93) | ECOG 0: 38.7% ECOG 1: 51.6% Hispanic: 74% |
CPA 71% CPB: 29% BCLC C: 86.1% Cirrhosisetiology: HCV 61% EtOH 52% |
13.5 mo | 6.2 mo | Grade 3: Fatigue (9.7%) HFS (16.1%) Reduced dose: 70% |
n = number, ECOG = Eastern Cooperative Oncology Group, DM = Diabetes mellitus, CVD = cardiovascular disease, CPA = Child-Pugh A cirrhosis, CPB = Child-Pugh B cirrhosis, BCLC = Barcelona Clinic Liver Cancer, CLIP = Cancer of the Liver Italian Program, HCV = hepatitis C virus, HBC = hepatitis B virus, mo = months, n/a = not available, EtOH = alcoholic, IADLs = instrumental activities of daily living, ADLs = activities of daily living, HTN = hypertension, CCI = Charlson Comorbidity Index, NASH = non-alcoholic steatohepatitis, HFS = hand-foot syndrome.